GLO1 overexpression in human malignant melanoma

Melanoma Research

Volumn 20, Issue 2, 2010, Pages 85-96

  Bair III, Warner B ^a   Cabello, Christopher M ^a   Uchida, Koji ^b   Bause, Alexandra S ^a   Wondrak, Georg T ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Glyoxalase I; Heat shock protein 27; Malignant melanoma; Methylglyoxal; Protein adduction

Indexed keywords

EPITOPE; HEAT SHOCK PROTEIN 27; LACTOYLGLUTATHIONE LYASE; MESSENGER RNA; METHYLGLYOXAL; SMALL INTERFERING RNA;

ARTICLE; CANCER TISSUE; CELL LYSATE; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MELANOMA; MELANOMA CELL; METASTASIS; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROCESSING; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

BLOTTING, WESTERN; CELL SEPARATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LACTOYLGLUTATHIONE LYASE; MELANOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TRANSFECTION;

EID: 77949561004     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283364903     Document Type: Article

References (58)

1. Thornalley PJ. Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. Crit Rev Oncol Hematol 1995; 20:99-128.
2. Ranganathan S, Ciaccio PJ, Walsh ES, Tew KD. Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. Gene 1999; 240:149-155.
3. Thornalley PJ. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems-role in ageing and disease. Drug Metabol Drug Interact 2008; 23:125-150.
4. Miyata T, van Ypersele de Strihou C, Imasawa T, Yoshino A, Ueda Y, Ogura H, et al. Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. Kidney Int 2001; 60:2351-2359.
5. Miller AG, Smith DG, Bhat M, Nagaraj RH. Glyoxalase I is critical for human retinal capillary pericyte survival under hyperglycemic conditions. J Biol Chem 2006; 281:11864-11871.
6. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 1998; 101:1142-1147.
7. Kawase M, Tada M, Akagi S, Ohmori S. Changes in concentrations of methylglyoxal, D-lactate and glyoxalase activities in liver and plasma of rats fed a 30-methyl-4-dimethylaminoazobenzene-rich diet. Res Exp Med (Berl) 1996; 196:251-259.
8. Van Heijst JW, Niessen HW, Hoekman K, Schalkwijk CG. Advanced glycation end products in human cancer tissues: detection of Nepsilon- (carboxymethyl) lysine and argpyrimidine. Ann N Y Acad Sci 2005; 1043:725-733.
9. Van Heijst JW, Niessen HW, Musters RJ, Hinsbergh VW, Hoekman K, Schalkwijk CG. Argpyrimidine-modified heat shock protein 27 in human non-small cell lung cancer: a possible mechanism for evasion of apoptosis. Cancer Lett 2006; 241:309-319.
10. Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T, Tsuruo T. Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin Cancer Res 2001; 7:2513-2518.
11. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006; 9:425-434.
12. Rulli A, Carli L, Romani R, Baroni T, Giovannini E, Rosi G, et al. Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res Treat 2001; 66:67-72.
13. Samadi AA, Fullerton SA, Tortorelis DG, Johnson GB, Davidson SD, Choudhury MS, et al. Glyoxalase I phenotype as a potential risk factor for prostate carcinoma. Urology 2001; 57:183-187.
14. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002; 2:76-84.
15. Ranganathan S, Walsh ES, Tew KD. Glyoxalase I in detoxification: studies using a glyoxalase I transfectant cell line. Biochem J 1995; 309:127-131.
16. Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M, et al. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 2000; 95:3214-3218.
17. Sharkey EM, O'Neill HB, Kavarana MJ, Wang H, Creighton DJ, Sentz DL, et al. Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I. Cancer Chemother Pharmacol 2000; 46:156-166.
18. Santel T, Pflug G, Hemdan NY, Schafer A, Hollenbach M, Buchold M, et al. Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity. PLoS One 2008; 3:e3508.
19. Meyskens FL Jr, Farmer PJ, Yang S, Anton-Culver H. New perspectives on melanoma pathogenesis and chemoprevention. Recent Results Cancer Res 2007; 174:191-195.
20. Wondrak GT, Jacobson MK, Jacobson EL. An emerging molecular target in melanoma: cellular carbonyl stress and the inhibition of mitochondrial survival pathways by carbonyl scavenger agents. Curr Cancer Ther Rev 2005; 1:271-276.
21. Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 2009; 45:1807-1814.
22. Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ, et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 2007; 117:719-729.
23. Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H, Choei H, et al. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 2004; 122:461-467.
24. Wondrak GT, Jacobson MK, Jacobson EL. Antimelanoma activity of apoptogenic carbonyl scavengers. J Pharmacol Exp Ther 2006; 316:805-814.
25. Amicarelli F, Bucciarelli T, Poma A, Aimola P, Di Ilio C, Ragnelli AM, et al. Adaptive response of human melanoma cells to methylglyoxal injury. Carcinogenesis 1998; 19:519-523.
26. Kremer CL, Klein RR, Mendelson J, BrowneW, Samadzedeh LK,Vanpatten K, et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006; 66:1203-1212.
27. Cabello CM, Bair WB III, Bause AS,Wondrak GT. Antimelanoma activity of the redox dye DCPIP (2,6-dichlorophenolindophenol) is antagonized by NQO1. Biochem Pharmacol 2009; 78:344-354.
28. Cabello CM, Bair WB III, Lamore SD, Ley S, Bause AS, Azimian S, et al. The cinnamon-derived Michael acceptor cinnamic aldehyde impairs melanoma cell proliferation, invasiveness, and tumor growth. Free Radic Biol Med 2009; 46:220-231.
29. Cabello CM, Bair WB III, Ley S, Lamore SD, Azimian S, Wondrak GT. The experimental chemotherapeutic N(6)-furfuryladenosine (kinetin-riboside) induces rapid ATP depletion, genotoxic stress, and CDKN1A (p21) upregulation in human cancer cell lines. Biochem Pharmacol 2009; 77:1125-1138.
30. Wondrak GT. NQO1-activated phenothiazinium redox cyclers for the targeted bioreductive induction of cancer cell apoptosis. Free Radic Biol Med 2007; 43:178-190.
31. Oya T, Hattori N, Mizuno Y, Miyata S, Maeda S, Osawa T, et al. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J Biol Chem 1999; 274:18492-18502.
32. Du J, Suzuki H, Nagase F, Akhand AA, Ma XY, Yokoyama T, et al. Superoxidemediated early oxidation and activation of ASK1 are important for initiating methylglyoxal-induced apoptosis process. Free Radic Biol Med 2001; 31:469-478.
33. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999; 24:68-72.
34. Bedogni B, Powell MB. Hypoxia, melanocytes and melanoma-survival and tumor development in the permissive microenvironment of the skin. Pigment Cell Melanoma Res 2009; 22:166-174.
35. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, et al. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 2004; 16:819-830.
36. Sakamoto H, Mashima T, Yamamoto K, Tsuruo T. Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification. J Biol Chem 2002; 277:45770-45775.
37. Speer O, Morkunaite-Haimi S, Liobikas J, Franck M, Hensbo L, Linder MD, et al. Rapid suppression of mitochondrial permeability transition by methylglyoxal. Role of reversible arginine modification. J Biol Chem 2003; 278:34757-34763.
38. Wondrak GT. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 2009; 11:3013-3069.
39. Yim HS, Kang SO, Hah YC, Chock PB, Yim MB. Free radicals generated during the glycation reaction of amino acids by methylglyoxal. A model study of protein-cross-linked free radicals. J Biol Chem 1995; 270:28228-28233.
40. Roberts MJ, Wondrak GT, Cervantes-Laurean D, Jacobson MK, Jacobson EL. DNA damage by carbonyl stress in human skin cells. Mutat Res 2003; 522:45-56.
41. Shipanova IN, Glomb MA, Nagaraj RH. Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct. Arch Biochem Biophys 1997; 344:29-36.
42. Yao D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino I, et al. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem 2007; 282:31038-31045.
43. Johans M, Milanesi E, Franck M, Johans C, Liobikas J, Panagiotaki M, et al. Modification of permeability transition pore arginine(s) by phenylglyoxal derivatives in isolated mitochondria and mammalian cells. Structure-function relationship of arginine ligands. J Biol Chem 2005; 280:12130-12136.
44. Oya-Ito T, Liu BF, Nagaraj RH. Effect of methylglyoxal modification and phosphorylation on the chaperone and anti-apoptotic properties of heat shock protein 27. J Cell Biochem 2006; 99:279-291.
45. Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, Diaz-Latoud C, et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol 2000; 2:645-652.
46. Garrido C, Ottavi P, Fromentin A, Hammann A, Arrigo AP, Chauffert B, et al. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res 1997; 57:2661-2667.
47. Garrido C, Schmitt E, Cande C, Vahsen N, Parcellier A, Kroemer G. HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle 2003; 2:579-584.
48. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005; 10:86-103.
49. Missotten GS, Journee-de Korver JG, De Wolff-Rouendaal D, Keunen JE, Schlingemann RO, Jager MJ. Heat shock protein expression in the eye and in uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44:3059-3065.
50. Carta F, Demuro PP, Zanini C, Santona A, Castiglia D, D'Atri S, et al. Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res 2005; 15:235-244.
51. Beere HM. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest 2005; 115:2633-2639.
52. Schalkwijk CG, Van Bezu J, van der Schors RC, Uchida K, Stehouwer CD, Van Hinsbergh VW. Heat-shock protein 27 is a major methylglyoxal-modified protein in endothelial cells. FEBS Lett 2006; 580:1565-1570.
53. Padival AK, Crabb JW, Nagaraj RH. Methylglyoxal modifies heat shock protein 27 in glomerular mesangial cells. FEBS Lett 2003; 551:113-118.
54. Brar SS, Kennedy TP, Sturrock AB, Huecksteadt TP, Quinn MT, Whorton AR, et al. An NAD(P)H oxidase regulates growth and transcription in melanoma cells. Am J Physiol Cell Physiol 2002; 282:C1212-C1224.
55. Fried L, Arbiser JL. The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res 2008; 21:117-122.
56. Fruehauf JP, Trapp V. Reactive oxygen species: an Achilles' heel of melanoma? Expert Rev Anticancer Ther 2008; 8:1751-1757.
57. Wittgen HG, van Kempen LC. Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res 2007; 17:400-409.
58. Cabello CM, Bair WB III,Wondrak GT. Experimental therapeutics: targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs 2007; 8:1022-1037.